Results 11 to 20 of about 9,369 (213)

Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme [PDF]

International Journal of Infectious Diseases, 2020
Background: Cryptococcal meningitis (CM) is estimated to cause 181 000 deaths annually, with the majority occurring in Sub-Saharan Africa. Flucytosine is recommended by the World Health Organization as part of the treatment for CM.
Amir Shroufi, Nelesh P. Govender, Graeme Meintjes, John Black, Jeremy Nel, Mahomed-Yunus S. Moosa, Colin Menezes, Halima Dawood, Douglas Wilson, Laura Trivino Duran, Olawale Ajose, Richard A. Murphy, Thomas Harrison, Angela Loyse, Carol Ruffell, Gilles Van Cutsem   +15 more
doaj   +3 more sources

Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy [PDF]

Case Reports in Critical Care, 2015
Purpose. A case report evaluating flucytosine dosing in a critically ill patient receiving continuous renal replacement therapy. Summary. This case report outlines an 81-year-old male who was receiving continuous venovenous hemofiltration (CVVH) for ...
Megan E. Kunka, Elizabeth A. Cady, Heejung C. Woo, Melissa L. Thompson Bastin   +3 more
doaj   +2 more sources

Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa [PDF]

BMC Health Services Research, 2021
Background Cryptococcal meningitis in HIV-infected patients in sub-Saharan Africa accounts for three-quarters of the global cases and 135,000 deaths per annum. Current treatment includes the use of fluconazole and amphotericin B.
Jacqui Miot, Trudy Leong, Simbarashe Takuva, Andrew Parrish, Halima Dawood   +4 more
doaj   +2 more sources

Clonal Population of Flucytosine-Resistant Candida tropicalis from Blood Cultures, Paris, France [PDF]

Emerging Infectious Diseases, 2008
Candida tropicalis is a diploid ascomycetes yeast responsible for 4%–24% of candidemia. Resistance to flucytosine is rarely described for this species but was observed for 45 (35%) of 130 C.
Marie Desnos-Ollivier, Stéphane Bretagne, Claire Bernède, Vincent Robert, Dorothée Raoux, Elisabeth Chachaty, Elisabeth Forget, Claire Lacroix, Françoise Dromer   +8 more
doaj   +2 more sources

Epidemiological and Clinical Characteristics, Antifungal Susceptibility, and MLST-Based Genetic Analysis of Cryptococcus Isolates in Southern Taiwan in 2013–2020

Journal of Fungi, 2022
Cryptococcal meningoencephalitis (CM) is a treatable condition, but it leads to excessive morbidity and mortality. We collected 115 non-duplicated Cryptococcus clinical isolates during 2013–2020 in southern Taiwan to perform antifungal susceptibility ...
Yi-Chun Chen, Shu-Fang Kuo, Shang-Yi Lin, Yin-Shiou Lin, Chen-Hsiang Lee   +4 more
doaj   +1 more source

Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs [version 2; peer review: 2 approved, 1 approved with reservations]

Wellcome Open Research, 2022
Introduction: Access to and the cost of induction treatment for cryptococcal meningitis (CM) is rapidly changing. The newly-announced price for flucytosine ($0.75 per 500 mg pill) and possibly lower prices for liposomal amphotericin B (AmB-L) create ...
Amir Shroufi, Radha Rajasingham, Bruce Larson, Joseph N. Jarvis, Rita Oladele, Charles Muthoga, Tom M. Chiller, Alexander Jordan, Nelesh P. Govender   +8 more
doaj   +1 more source

Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans

Microbiology Spectrum, 2021
The high morbidity and mortality of cryptococcal meningitis is due to the limited range of therapeutic options: only three classes of antifungal drugs are available (polyenes [amphotericin B], azoles [fluconazole], and pyrimidine analogues [flucytosine]).
Feng Yang, Vladimir Gritsenko, Hui Lu, Cheng Zhen, Lu Gao, Judith Berman, Yuan-ying Jiang   +6 more
doaj   +1 more source

Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis. [PDF]

, 2023
BACKGROUND: There are limited data describing clinical flucytosine pharmacokinetics (PK). The variability of flucytosine partitioning into the CNS is not known.
Gondwe, Ebbie, Lawrence, David S., Moyo, M, Hope, W, Shah, RV, Jagota, Bhavana, Kajanga, Cheusisime, Kajanga, C, Ahmadu, Ajisa, Lawrence, David S, Mwandumba, HC, Jagota, B, Shah, Reya V., Lalloo, DG, Mwandumba, Henry, Harrison, T, Jarvis, JN, Lalloo, David G, Jimenez-Valverde, Ana, Jimenez-Valverde, A, Unsworth, Jennifer, Lawrence, DS, Stott, KE, Stott, Katharine E., Chasweka, M, Harrison, Tom, Gondwe, E, Moyo, Melanie, Mwandumba, Henry C, Stott, Katharine E, Shah, Reya V, Hope, William, Unsworth, J, Chimang'anga, Wezzie, Chimang'anga, W, Lalloo, David; id_orcid, Jarvis, Joseph N., Chasweka, Madalitso, Jarvis, Joseph N, Ahmadu, A   +39 more
core   +1 more source

Prevalence of cryptococcal meningitis among people living with human immuno-deficiency virus and predictors of mortality in adults on induction therapy in Africa: A systematic review and meta-analysis

Frontiers in Medicine, 2022
BackgroundCryptococcal meningitis (CM) is a leading cause of adult meningitis in countries with a high burden of HIV. It has remained a significant cause of morbidity and mortality in Africa despite the extensive rollout of HIV antiretroviral therapy ...
Seke G. Y. Muzazu, Seke G. Y. Muzazu, Dawit Getachew Assefa, Dawit Getachew Assefa, Christabel Phiri, Tewodros Getinet, Samrawit Solomon, Gizachew Yismaw, Tsegahun Manyazewal   +8 more
doaj   +1 more source

Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. [PDF]

, 2013
Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for ≥2 weeks as the initial induction treatment of choice.
A. Loyse, Dromer, F, Day, J, Lortholary, O, O. Lortholary, Harrison, TS, F. Dromer, Day, Jeremy, T. S. Harrison, J. Day, Loyse, A   +10 more
core   +1 more source